A total of 108 large health listed companies: 168.2 billion total size funds
In recent years, in the field of investment in the big health industry, listed companies have found more and more forms of investing in quality projects in the form of industrial funds. Taking this as a starting point, listed companies can reduce the impact of direct acceptance of mergers and acquisitions on the secondary market. The introduction of new technologies and new businesses is of obvious significance in promoting the business expansion and strategic transformation of listed companies. A number of cooperation, leveraged acquisitions and other methods have also reduced the pressure on listed companies' funds, coupled with the influx of PE and professional asset management institutions, and the establishment of industrial funds by listed companies has exploded.
The author has sorted out the 108 large-scale health industry funds initiated by listed companies with a total scale of 168.2 billion since 2015, trying to observe the development of the pharmaceutical industry from the perspective of industrial investment and mergers and acquisitions.
Section 1: Data Interpretation
Industry fund establishment time
In 2015, a total of 49 large health industry funds were announced. In 2016, this data was further expanded to 55. Just two months later this year, four large health funds were announced.
Fund size
Among the 108 industrial funds included in the statistics, 61 are under 1 billion, of which 13 are expected to be 300 million, 21 are 1 billion, accounting for about half of the total, and between 1 and 5 billion. health industry Fund 42, only five of more than 50 million, including bio-medical industry buyout funds Nanjingxinbai, three cell groups, Nanjing Peng Ying and information management, initiated the establishment of the Nanjing Bank, as well as the Galaxy Group initiated the establishment of the immunity Investment funds for treatment, stem cell clinical application platforms, macromolecular drugs and antibody drug development related fields, and the 20 million-year-old health industry global M&A fund initiated by China CITIC Bank and Sancell Group on January 20 this year.
field
Kidney Medicine powder,Seabuckthorn Extract Powder,Red Peony Root Extract,Lansoprazole Ingredients Powder,Nebivolol HCL Ingredients,
It has absolute advantage because of strong research strength, modern management system and high-quality marketing team.Now we have 3 GMP standard workshop, Meanwhile, the factory is equipped with the researching and quality inspection centre, with strong technology research and development strength. We also have 3 salesdepartments over 30 people and sell our products all over the world.
For customer`s needs, OEM service is also acceptable. If you have a good idea in new product production but lack of laboratory device and human resource, we are glad to solve this problem for you. Sincerely hope to strengthen exchanges and cooperation with friends from both home and abroad.
Kidney Medicine powder,Seabuckthorn Extract Powder,Red Peony Root Extract,Lansoprazole Ingredients Powder,Nebivolol HCL Ingredients
Xi'an Henrikang Biotech Co.,Ltd , https://www.xianhenrikangbio.com